GlassScriptPhysician profile
Weston Gordon
NPI 1942654322
$5,186.04
in general payments reported to CMS, 2019-2025
15 companies · $1,013 in 2025
The $1,013 reported for 2025 was more than what a typical Vascular Neurology provider received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.68 · 2020: $89.93 · 2022: $297 · 2023: $1,678 · 2024: $2,031 · 2025: $1,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,876 · Travel and Lodging: $1,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,875.51 |
| Travel and Lodging | $1,846.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Imperative Care, INC | $2,747.12 | 2022-2025 | Zoom 88-T Large Distal Platform, Zoom Reperfusion Catheter, Zoom Rdl Radial Access System, 103cm |
| Microvention, INC. | $1,342.80 | 2023-2024 | Sofia 6f-131cm Str, Eric Retrieval Device, Web Aneurysm Embolization System |
| Penumbra, INC. | $742.86 | 2020-2024 | Penumbra System, Penumbra Coil 400, Benchmark |
| Genentech, INC. | $76.68 | 2019 | |
| Abbvie INC. | $69.02 | 2024-2025 | |
| Argenx US, INC. | $42.01 | 2024-2025 | Vyvgart Hytrulo |
| Jazz Pharmaceuticals INC. | $24.17 | 2025 | |
| Tg Therapeutics, INC. | $20.70 | 2025 | |
| Neurocrine Biosciences, INC. | $20.60 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $19.15 | 2025 | Rexulti |
| Lilly USA, LLC | $18.27 | 2024 | Emgality |
| Astrazeneca Pharmaceuticals LP | $17.31 | 2023 | Andexxa |
| Tanabe Pharma America, INC. | $16.42 | 2024 | |
| Ucb, INC. | $16.25 | 2024 | Briviact |
| Livanova USA, INC. | $12.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weston Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.